Gene therapy. The legacy of Wacław Szybalski*

Józef Dulak

Department of Medical Biotechnology, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University, Kraków, Poland

Semineral demonstration of the possibility of stable genetic modification of mammalian cells performed by Wacław and Elisabeth Szybalski opened the doors for gene therapy, the term coined by Wacław Szybalski already in 1962. In the next 60 years, numerous tools for gene delivery have been developed and applied for clinical research, culminating in the registration of several genetic therapies in Europe and the USA. Some of these strategies, aimed to treat severe combined immunodeficiencies, inherited forms of blindness, spinal muscular atrophy, some cancers, and genetic anemias, are the real hope for patients suffering from previously incurable diseases or the ones whose treatment was not effective. On the approaching 60th anniversary of gene therapy, combined with the 100th anniversary of the birth of Professor Wacław Szybalski (September 9th, 1921), who passed away on December 16, 2020, here I present the summary of the most important aspects of clinical applications of genetic therapies.

Keywords: retroviral vectors, self-inactivating lentiviral vectors, AAV vectors, adenoviral vectors, CRISPR/Cas9, gene editing, Duchenne muscular dystrophy, spinal muscular atrophy, severe combined immunodeficiencies, β-thalassemia, sickle cell anemia, CAR-T, antisense oligonucleotides, siRNA

Received: 29 July, 2021; revised: 31 July, 2021; accepted: 31 July, 2021; available on-line: 31 August, 2021

E-mail: jozef.dulak@uj.edu.pl
*This paper is dedicated to the memory of Professor Wacław Szybalski and Professor Anna Podhajska, whom I had the honor to meet for the first time in 1994 and who have been instrumental in developing my interest in medical biotechnology, and especially in gene therapy.

Acknowledgements of Financial Support: Financial support: MAESTRO 10 grant (2018/30/A/ZZ3/00412) from the National Science Center (NCN), CISTEM MSCA RISE (Z/2020/0023) from the H2020 program (grant agreement No. 778354), and NMJ-on-a-chip (UMO-2019/01/Y/NZ3/00012) from the JPND initiative (Horizon 2020) and NCN.

Abbreviations: AAV, adeno-associated viruses; ADA-PEG, adenosine deaminase-polyethylene glycol; ADA-SCID, adenosine deaminase-severe combined immunodeficiency syndrome; AIDS, acquired immunodeficiency syndrome; ALD, adrenoleukodystrophy; ALL, acute lymphoblastic leukemia; a-Gal, a-galactosidase A; BCLA11A, BAF Chromatin Remodeling Complex Subunit BCL11A; BCMA, B-cell maturation antigen; CAR, chimeric antigen receptor; CAR–T cells, chimeric antigen receptor T cells; CCR5, C-C chemokine receptor type 5; cDNA, complementary DNA; CD3, cluster of differentiation 3; CD19, cluster of differentiation 19; CD34, cluster of differentiation 34; CEP290, centrosomal protein 290; CGD, chronic granulomatous disease; c-Myc, c-Myc oncogene; COVID-19, coronavirus disease 2019; CRISPR/Cas9, clustered regulared interspaced short palindromic repeats; CRISPR-associated 9; CSF3, colony stimulating factor 3; DMD, Duchenne muscular dystrophy; DNA, deoxyribonucleic acid; EB, epidermolysis bullosa; EMA, European Medicines Agency; ESC, embryonic stem cells; FDA, Food and Drug Administration; GM, globastoma multiforme; HAT medium, hypoxantine-aminopterin-thymidin medium; HATTR, hereditary transthyretin-mediated amyloidosis; HEK-293 cells, human embryonic kidney 293 cells; HIV, human immunodeficiency virus; HNRNP-A1, heterogeneous nuclear ribonuleoprotein A1; HPRT, hypoxanthine-guanine phosphoribosyl transferase; HR, homologous recombina-

INTRODUCTION

Traditionally, gene therapy is considered as the treatment of diseases caused by a defined genetic mutation, which can be overcome by restoration of expression of the correct version of a gene. Nevertheless, the idea of gene therapy has very much evolved from the original definition. While the replacement therapy, i.e. introducing the non-mutated version of the gene to substitute the faulty one, is still the bona fide gene therapy, one has to be aware that the genetic approaches, which are targeted at the molecular background of the diseases and employ the genetic strategies or nucleic acids as the medicines, are currently much more diverse. Hence, the dogmatic view on gene therapy is no longer valid, and the statement that only replacement gene therapy represents the original one is unjustified, similarly to the belief that one gene encodes one protein. We are now fully aware of the complexity of the gene structure, but this does not abolish the validity and importance of the original “one gene – one protein” hypothesis. Similarly, the founding statements that gene therapy is about restoring the proper version of the gene does not mean that it is limited only to such an approach.

Gene transfer with engineered vectors became a routine tool for research and is applied in numerous experimental therapies in animal models. According to the Gene Therapy Clinical Trials Worldwide (Journal of Gene Medicine site – GTCT (FMS19) (fmphost.com)), up to this year, 3180 clinical trials of gene therapy have been performed, with more than 800 gene therapy trials ongoing in clinical development (High & Roncarolo, 2019). The first officially approved clinical trial of gene therapy has been performed in 1991, and up to date six gene therapies have been registered in Europe and the USA (Table 1). This number comprises classical
gene therapies in which the correct versions of mutated genes are introduced into the patients either directly, by an \textit{in vivo} approach, or the disease is treated by an \textit{ex vivo} modification of stem or progenitor cells which are then infused back into the patient. Nevertheless, numerous research has led in fact to development and registration of more than 20 genetic therapies in which nucleic acids are used to cure the diseases (Table 1). This is exemplified by modification of T-lymphocytes to improve their elimination of cancer cells (CÂR-T cell therapies) (Ellis et al., 2021), and the application of siRNA or antisense oligonucleotides to remove the mutated nucleic acid, or antisense oligonucleotides to repair the mutation by exon skipping or exon inclusion (for review see: Winkle et al., 2021). In a much broader sense, genetic therapies also involve application of the coding mRNA sequences, which in the last year became famous thanks to the development of mRNA vaccines against SARS-CoV-2. The same concerns also DNA-based (adenoviral) anti-SARS-CoV-2 vaccines.

\section*{GENE DELIVERY TOOLS}

When Waclaw and Elizabeth Szybalski performed the first effective genetic modification of mammalian cells, they have used DNA isolated from healthy cells and introduced it into cells lacking the hypoxanthine-guanine phosphoribosyl transferase (HPRT) enzyme (Szybalska \\& Szybalski, 1962). Such cells were not able to grow in the HAT medium, designed by them, which contains hypoxanthine, aminopterin, and thymidine. The Szybalski's experiment was even destined to failure, because the free nucleic acid is negatively charged and cannot normally enter the cells (as the so-called naked DNA) into the mammalian cells due to the negatively charged cell membrane and other barriers, like extracellular matrix. Currently, we apply various positively charged molecules, such as cationic liposomes, polyamines, and dendrimers that neutralize the negative charge of DNA and change it to a positive one, which allows the DNA or RNA to enter into the cells (Fig. 1) (for review see: Belmadi et al., 2015). Nevertheless, the successful modification achieved by Szybalski was possible thanks to the high concentration of calcium ions used for DNA precipitation, which neutralized the negative charge of DNA (Prof. Waclaw Szybalski: personal communication).

The idea of gene therapy as a way to introduce the correct version of the mutated gene for the treatment of diseases was then coined by Waclaw Szybalski and proposed at a series of conferences (for references see: Szybalski, 2013). The sixties and seventies of the former century were the time of development of various tools to modify the cells, with the application of calcium chloride and dextran sulfate as the effective methods for gene delivery (Table 2). They were, however, impractical from the point of \textit{in vivo} gene transfer. The beginning of genetic engineering, initiated by the discovery of restriction enzymes and ligases, allowing manipulation of nucleic acids through cutting and joining various sequences, led to the applications of plasmid vectors for the delivery of genes to mammalian cells. Nevertheless, an efficient genetic modification of mammalian cells and its application \textit{in vivo} became possible only when the knowledge on the structure and biology of viruses allowed their modification to use them as safe viral vectors (for review see: (Wirth et al., 2013)) (Fig. 1).

\section*{VIRAL VECTORS}

Viral vectors are the most commonly used tools for gene therapy, with the retroviral/lentiviral, adenoviral,
Table 2. Some major milestones and achievements in gene therapy

<table>
<thead>
<tr>
<th>Year</th>
<th>Milestone/achievement</th>
<th>Who/where</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>1962</td>
<td>First effective modification of mammalian cells by delivery of DNA from healthy cells</td>
<td>Waclaw and Elisabeth Szybalski</td>
<td>HPRT-lacking cells were successfully transfected thanks to the high concentration of calcium ions in the media</td>
</tr>
<tr>
<td>1970s–1990s</td>
<td>Calcium phosphate, liposomes, dendrimers for transfection of non-viral vectors (plasmids)</td>
<td>Many researchers</td>
<td>Effective for in vitro delivery; liposomes are also currently used for the delivery of mRNA based anti-SARS-COV-2 vaccines</td>
</tr>
<tr>
<td>1970s–1990s</td>
<td>Genetic engineering – plasmid vectors used for gene transfer; manipulation of retroviral, adenoviral, and AAV vectors</td>
<td>Many researchers</td>
<td>Development of packaging cells (such as HEK293) allowed efficient production of high titer vectors; usage of naturally occurring serotypes and genetic manipulation permits targeting vectors to different cell types; problems exist with the immune response to vectors due to pre-existing antibodies; problems with insertional mutagenesis in case of retroviral vectors</td>
</tr>
<tr>
<td>1989</td>
<td>Retroviral vector’s first modification of patients’ cells</td>
<td>Steven Rosenberg et al. NIH Bethesda, USA</td>
<td>Terminally sick melanoma patients received an infusion of autologous leukocytes transduced with the retroviral vector</td>
</tr>
<tr>
<td>1991</td>
<td>First gene therapy trial – ADA-SCID</td>
<td>Michael Blaese et al. NIH Bethesda, USA</td>
<td>Patient died from retroviral vector problems in addition to ADA-PEG</td>
</tr>
<tr>
<td>1999</td>
<td>Death of Jesse Geisinger in the clinical trial of gene therapy for ornithine transcarbamylase deficiency</td>
<td>Philadelphia, USA</td>
<td>This death was due to the pre-existing immunity to adenoviruses which aggravated when large doses of adenoviral vector were injected into the patient</td>
</tr>
<tr>
<td>2000</td>
<td>First successful retroviral gene therapy of X-SCID</td>
<td>Marina Cavazanna-Calvo &amp; Alain Fischer, Paris</td>
<td>Similar studies at the same time initiated by Adrian Thrasher et al. in London</td>
</tr>
<tr>
<td>2003</td>
<td>T-cell lymphoproliferative disease in 25% patients of X-SCID trials</td>
<td>Paris &amp; London</td>
<td>Four patients in Paris, one in London (one patient died, others effectively cured); Leukemia developed as the consequence of vector integration into LMO2 oncogene</td>
</tr>
<tr>
<td>2006 &amp; 2007</td>
<td>Induced pluripotent stem cells (iPSC) achieved by genetic reprogramming of somatic cells (retroviral overexpression of four transcription factors: Oct4, Sox2, Klf4 and c-Myc)</td>
<td>Shinya Yamanaka, Kyoto, Japan</td>
<td>Nobel prize in 2012 (together with John Gurdon); iPSCs became the tool for disease modelling and therapy</td>
</tr>
<tr>
<td>2012</td>
<td>Glybera (aliplane tiparvovec)</td>
<td>UniQure (The Netherlands)</td>
<td>AAV1 vector with LPL gene injected into the muscles</td>
</tr>
<tr>
<td>2013</td>
<td>Gene editing by CRISPR/Cas9</td>
<td>proposed by Emanuella Charpentier, Jennifer Doudna, and Virginijus Siksnys</td>
<td>2018 – Kavli prize for E. Charpentier, J. Doudna and V. Siksnys 2020 – Nobel prize for E. Charpentier and J. Doudna</td>
</tr>
<tr>
<td>2015</td>
<td>Oncolytic herpes virus talimogene laherparepvec (HSV1-GM-CSF)</td>
<td>Imlygic, Amgen</td>
<td>Approved for melanoma; intratumoral injection</td>
</tr>
<tr>
<td>2016</td>
<td>Stimmvirus registered (autologous CD34+ transduced with retroviral vector harbouring adenosine deaminase gene)</td>
<td>Orchard Therapeutics (the strategy was developed in San Raffaele Hospital in Milan)</td>
<td>In contrast to X-SCID, CGD and Wiskott-Aldrich gene therapy, the insertional mutagenesis has not occurred in ADA-SCID gene therapy (however, recent report suggests that it might have occurred in one patient)</td>
</tr>
<tr>
<td>2016</td>
<td>Nusinersen (Spinraza) – antisense oligonucleotide targeting exon to restore proper splicing of SMN2 gene and synthesis of SMN protein</td>
<td>Ionis Pharmaceuticals/Biogen</td>
<td>Injected intrathecally (oligonucleotides do not cross the blood-brain barrier); has to be given every four months; applicable to all SMA patients</td>
</tr>
<tr>
<td>2016</td>
<td>First patient treated with the iPSC-derived cells</td>
<td>Masayo Takahashi, Kobe, Japan</td>
<td>Autologous iPSC differentiated into retinal epithelial cells to treat adult macular degeneration</td>
</tr>
<tr>
<td>2017</td>
<td>First CAR-T therapy registered by FDA: Tisagenlecleucel (Kymriah) (in 2018 by EMA)</td>
<td>Novartis/Lite Pharma Kite Therapeutics</td>
<td>Autologous gene-modified T -cells for intravenous infusion For ALL refractory patients younger than 25 yr of age For certain types of non-Hodgkin lymphoma</td>
</tr>
<tr>
<td>2020 – Nobel prize for E. Charpentier and J. Doudna</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
2017  Voretigene neparovect-rzyl (Luxturna) registered in USA (in 2018 in Europe) Spark Therapeutics AAV2-vector harboring RPE65 cDNA for RPE65 Leber's congenital amaurosis; injected subretinally

2017  Gene therapy for junctional epidermolysis bullousa – autologous epidermal progenitors modified with retroviral vector harboring LAMB3 cDNA Hirsch et al (M. De Luca, G. Pellegrini) – Bochum, Germany & Modena, Italy Five years after the treatment which restored the healthy epidermis the patient is in very good conditions

2019  Onasemnogene abeparvovec (Zolgensma) Novartis AAV9-SMN1 by intravenous infusion

2019  Conditional approval of Zynteglo (betibeglogene autotemcel) bluebird bio Modification of autologous CD34+ cells with lentiviral vector harboring the proper β-globin gene

2020  EMA approves Limbeldy (OTL-200) Orchard Therapeutics & San Raffaele – Telethon Institute (Milan) Autologous CD34+ cells transduced with lentiviral vector harboring human arylsulfatase-A (ARSA) gene for metachromatic leukodystrophy

2020  mRNA and adenosivl vaccines for SARS-COV-2 mRNA – Pfizer/BioNtech Moderna – AstraZeneca; Janssen, Gamaleya Hundreds of millions of people vaccinated in December 2020 and the first half of 2021

2020  CRISPR/Cas9 gene-editing applied to Leber's congenital amaurosis patients Allergan & Edatas Medicine at Oregon Health and Science Medicine Center Subretinal injection of sgRNA/Cas9 (AGN-151587 (EDIT-101) targeted to a mutation in the CEP290 gene

2021  Gene editing & gene inhibition for the treatment of β-thalassemia and sickle cell disease Vertex Pharmaceuticals & CRISPR Therapeutics bluebird bio CRISPR/Cas9 gene-editing of BCL11A enhancer in CD34+ cells allows switching on the fetal γ-globin expression and appears to be effective in two treated patients shRNA inhibition of BCL11A gene

2021  Abecma (idecabtagene vicleucel) registered by the FDA Bristol Myers Squibb CAR-T cells therapy for relapsed or refractory multiple myeloma patients – directed against B-cell maturation antigen CAR-T cells therapy for the treatment of adult patients with refractory or relapsed large B-cell lymphoma

Table 3. Advantages and drawbacks of major viral vectors used in gene therapies

<table>
<thead>
<tr>
<th>Type of vector</th>
<th>Features</th>
<th>Advantages</th>
<th>Risk and limitations</th>
<th>Mitigation approaches for potential problems/other approaches</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gamma-retroviral</td>
<td>Capacity ~8kb (in case of helper-dependent vectors), usually less, ~8.5 kb</td>
<td>Very well-known biology, ease of manipulation, Integration – propensity for gene regulatory regions</td>
<td>Self-inactivating lentiviral vectors Risk of insertional mutagenesis may be also linked with the transgene</td>
<td></td>
</tr>
<tr>
<td>Lentiviral</td>
<td>Capacity ~ 8kb</td>
<td>Infect non-dividing cells</td>
<td>Difficulties in production Long term studies not yet known</td>
<td>Self-inactivating vectors Restriction of expression to a given cell type by e.g. incorporation of miRNA recognition sequence in 3'UTR</td>
</tr>
<tr>
<td>Adenoviral</td>
<td>Capacity up to 38 kb (in case of helper-dependent vectors), usually less, ~8.5 kb</td>
<td>Easily infect numerous cell types independently of cell cycles; Large scale and high titer production possible</td>
<td>High risk of systemic inflammation Preexisting immunity diminishes expression efficacy</td>
<td>Elimination of viral sequences to limit the inflammatory response Change of serotype for the 2nd injection</td>
</tr>
<tr>
<td>AAV</td>
<td>Capacity up to 4.5 kb</td>
<td>Non-pathogenic Permanent transduction of the post-mitotic cells – neurons, skeletal myoblasts, cardiomyocytes Several serotypes demonstrating tropism for specific cell types</td>
<td>Size of the transgene vs size of the gene – this is a drawback in case of DMD, not in the case of SMA Risk of side effect – immune response – antibodies to capsid; activation of cytotoxic T lymphocytes killing transduced cells; Immunity against transgene protein, e.g. dystrophin (but not the case for SMN, as its small amount is produced from the SMN2 gene)</td>
<td>Various serotypes to target specific cells Delivery of truncated version of the gene (microdystrophins for DMD; shortened factor VIII for treatment of hemophilia A)</td>
</tr>
</tbody>
</table>
and adeno-associated viral (AAV) vectors comprising the vast majority of application in clinical trials of gene therapies (see The Gene Therapy Clinical Trials Worldwide: https://a873679.fmhost.com/fmi/webdl/GTCT) (Fig. 1, Table 3). The strategy of their application for treatment of patients relies on the removal of unnecessary genes, particularly those which are responsible for pathogenicity of the virus, making the vectors safe but still retaining the capacity to deliver nucleic acid into the cells (for reviews see: (Giacca & Zacchigna, 2012; Dunbar et al., 2018; High & Roncarolo 2019; Li & Samulski, 2020). First of all, the genes responsible for viral replication are removed in order to prevent replication of the vector after injection into the patient. Second, additional genes are removed to restrict the immune reaction to the vectors and to increase the capacity for the transgene (therapeutic gene). In the case of integrating retroviral/lentiviral vectors, the modifications also concern the sequences which may limit the effect of integration in the unwanted sites. The latter and other modifications arise as the result of side effects observed in early clinical trials (see below). Hence, the potential and safety of future genetic therapies will hopefully increase thanks to the combination of basic research and observation of the outcomes of clinical trials.

The consequence of such manipulations is dependent on the type of the vector. First, various vectors have different packaging capacities, hence their application for delivery of a given sequence may be dictated by the size of the viral genome (Table 3). Second, depending on the viral properties, the vector can allow only for the transient modification of the cells, as without integration the vector is lost by the dividing cells. Nevertheless, even non-integrating vectors can provide long-term expression in post-mitotic cells, such as muscle fibers or neurons, if they are not eliminated by the immune response (Li & Samulski, 2020). Third, the efficacy of transduction may depend on the cell cycle state of the cell being transduced, as some vectors transduce only the dividing cells due to their inability to pass the nuclear membrane. This is the case of the gamma-retroviral vectors which unlike the lentiviral vectors cannot transduce cells when they do not proliferate (High & Roncarolo, 2019).

The persistence of the introduced gene expression is dependent not only on the integration, but also on the immunogenicity of the vector used. As a large number of viral particles is injected into the patient and in the same way the amount of viral proteins particularly present in the capsid are exposed to the immune system of the patient, the pre-existing immunity may lead to rapid elimination of the vector and vanishing of the efficacy of therapy. This is of concern for adenoviral and to a lesser extent for AAV vectors, as the pre-existing neutralizing antibody can lead to vector elimination, but can also cause a strong inflammatory response, particularly in the case of adenoaviral vectors. In an extreme situation, this can create the risk of death, as it, unfortunately, happened in the well-known ornithine transcarbamylase (OTC) trial in 1999, when 18-years old Jesse Gelsinger had died a few days after intravenous injection of the OTC-harboring adenovirus (Dunbar et al., 2018). The same concerns the potential risk of the lower effectiveness of the adenoaviral-based vaccines, although the ongoing “life” trials with the anti-SARS-CoV-2 vaccines indicate that the fears may not be fulfilled.

The critical problem associated with the vectors’ safety is their capacity to integrate into the cell genome. While the permanent cell modification is necessary for the life-long effect of gene therapy in inherited diseases, the usually random vector integration exposes patients to the risk of side effects that have to be balanced with the benefits of the therapy. This is the best exemplified in the case of gene therapy of immunodeficiency syndromes, in which the hematopoietic stem and progenitor cells (HSPC) are transduced with retroviral vectors. In original studies with the treatment of the X-linked severe combined immunodeficiency syndrome (X-SCID) (see below), modified gamma-retroviral vectors have been used. These trials have demonstrated high efficacy resulting in the restoration of the immune system of boys suffering from the lack of the proper γc chain gene, the mutation responsible for this X-SCID form of immunodeficiency. However, within a few years after therapy, 25% of boys experienced an uncontrolled T cell proliferative response due to vector integration in the promoter of the LMO2 gene, leading to an acute T-cell lymphoproliferative disorder (Staal et al., 2019; Kohn

Figure 2. Regulation of gene expression used in experimental gene therapies
All of the above-discussed types of vectors have been applied in registered clinical gene therapies, which will be briefly described below. However, it is not possible here to discuss numerous aspects of experimental gene therapy in different diseases, and the readers are therefore referred to other, excellent reviews (Dunbar et al., 2018; High & Roncarolo, 2019; De Luca et al., 2019; Korpela et al., 2021).

**CLINICAL APPLICATIONS OF GENE THERAPY**

Coincidentally, close to the time when Wacław and Elisabeth Szymbalski had been performing their experiments, the rare genetic disease, caused by a mutation in the X chromosome-located HPRT gene, has been recognized by Michael Lesch and William Nyhan. This severe neurological disease, manifested by autoaggressive, self-mutilating behavior of affected patients, and development of uric acid stones in the kidneys and joints is since that time named the Lesch-Nyhan syndrome (Kelley & Andersson, 2014). Unfortunately, despite the enormous development of gene therapy strategies, the Lesch-Nyhan syndrome is not treatable, due to the complexity of this genetic disorder, which would most probably require gene therapy early in life, even in utero, and difficult if not impossible manipulation of the nervous system cells.

Nevertheless, it took almost 30 years till the time when the first controlled clinical trials of gene therapy have been performed. Historically, the first vectors applied for human gene therapy were the retroviral ones. In 1989 the first controlled transduction of lymphocytes of a patient suffering from end-stage melanoma was performed (Rosenberg et al., 1990). The approach was aimed not to treat the disease, but to demonstrate the feasibility of the retroviral vectors to stably modify the cells. The marker gene, encoding bacterial neomycin transferase, was incorporated into the retroviral backbone and the tumor-infiltrating lymphocytes of the patient collected two months after delivery demonstrated its expression (Rosenberg et al., 1990; Culver et al., 1991).

**Gene therapy of severe combined immunodeficiencies**

In the next years, retroviral vectors were used to modify the cells of severely immunodeficient patients suffering from adenosine deaminase-type of the disease (ADA-SCID). The first controlled clinical trial of gene therapy for this type of immunodeficiency was performed in two girls at NIH in Bethesda by Blaese and co-workers in 1991 (Culver et al., 1991). The outcome was successful, as the modified cells were found in their blood 4 years after the injection (Blaese et al., 1995) and some, although very rare, modified lymphocytes were detected after 12 years (Muul et al., 2003). Nevertheless, from the scientific point of view, the experiment was not stringent enough. Due to various reasons, the patients have not been treated only with the genetically modified cells, but have been also injected with the then-registered ADA-PEG. As this ready-to-use enzyme appeared to be the effective treatment for those ADA-SCID patients who do not qualify for the allogeneic bone marrow transplantation, the outcome of the first gene therapy cannot be ascribed only to the effect of genetically modified cells. However, ADA-PEG has to be given throughout the whole life, the cost of the treatment is high (Table 4), and there is a risk of development of intolerance.

In 2000, another, fully successful gene therapy has been reported by French researchers. The team of...
Marina Cavazzana and Alain Fischer from the Necker Hospital in Paris have treated boys suffering from the X-SCID, caused by a mutation in the γc chain of the interleukin receptor (IL2RG) (Cavazzana-Calvo et al., 2000). The disease is fatal if not treated by bone marrow transplantation and the patients, named “bubble boys”, are at a risk of death due to even mild infections. Moreover, unlike the ADA-deficiency, this disease cannot be treated by an enzyme replacement therapy, as the γc protein is membrane-bound. Allogeneic bone marrow transplantation is the therapy of choice for the X-SCID patients, however, its success is limited, associ-

Table 4. Costs of some registered and conditionally approved genetic therapies in Europe and the USA

<table>
<thead>
<tr>
<th>Drug (producer/supplier)</th>
<th>Vector /type of nucleic acid</th>
<th>Indication</th>
<th>Number of patients to be treated</th>
<th>Cost per dose/patient</th>
<th>Management therapies/other therapies available</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glybera (UniQure)</td>
<td>AAV1 with LPL gene</td>
<td>Lipoprotein lipase deficiency (LPLD) prevalence of LPLD – 1-2 per million; till 2018 only 31 patients treated (but mostly in clinical trials, as the price of the drug was restrictive – finally the drug has been withdrawn from the market)</td>
<td>Approx. 15 patients/year in Europe; 12 in the USA</td>
<td>1.2 million €</td>
<td>Restricting fat in diet; lipid-lowering therapy (not sufficiently effective)</td>
</tr>
<tr>
<td>Strimvelis (GlaxoSmithkline/Orchard Therapeutics)</td>
<td>CD34+ modified with ADA gene (lentiviral)</td>
<td>ADA -SCID</td>
<td>Approx. 15 patients/year in Europe; 12 in the USA</td>
<td>594,000 €</td>
<td>Enzyme replacement (ADA-PEG) – ~ 3.6 million € for one patient over 4 years</td>
</tr>
<tr>
<td>Luxturna (Spark Therapeutics/Novartis)</td>
<td>AA2 with RPE65 gene</td>
<td>RPE65 mutation (Leber's congenital amaurosis)</td>
<td>1,000-2,000 in the USA; 10-20 children born/year</td>
<td>360,000 €/eye total</td>
<td>No other efficient therapy available</td>
</tr>
<tr>
<td>Zolgensma (Novartis)</td>
<td>AAV9 with SMN1 gene</td>
<td>Spinal muscular atrophy</td>
<td>About 800 patients in Poland; 30-50/year</td>
<td>1.8 million € (52,100,000 in US; or $ 425,000/year over 5 years)</td>
<td>Spinraza (see below)</td>
</tr>
<tr>
<td>Spinraza (Ionis Pharmaceuticals/Biogen)</td>
<td>Antisense oligonucleotide</td>
<td>Spinal muscular atrophy</td>
<td>As above</td>
<td>635,000 €/1st year 318,000 € thereafter</td>
<td>Zolgensma (see above)</td>
</tr>
<tr>
<td>Kymriah (Novartis)</td>
<td>CAR-T for CD19 antigen common on B cells</td>
<td>B-cell acute lymphoblastic leukemia (ALL) – 16–19% of non-Hodgkin lymphoma</td>
<td>2,500 case/year in the USA; roughly 600 do not respond to standard treatment</td>
<td>400,000 € ($475,000)</td>
<td>The cost of the drug does not include the cost of management of the cytokine release syndrome &amp; other complications</td>
</tr>
<tr>
<td>Yescarta (axicabtagene ciloleucel) (Kite Pharma/Gilead)</td>
<td>CAR-T for CD19 antigen</td>
<td>Diffuse Large B-cell lymphoma</td>
<td>24,000 cases/year in the USA</td>
<td>316,000 € ($373,000)</td>
<td>As above</td>
</tr>
<tr>
<td>Tecartus (brexucabtagene autoleucel) (Kite Pharma/Gilead)</td>
<td>CAR-T for CD19 antigen</td>
<td>Mantle cell lymphoma (a subset of non-Hodgkin lymphoma)</td>
<td>15,000 patients in the USA</td>
<td>316,000 € ($373,000)</td>
<td>Similar as Yescarta, targets the same CD19 antigen, different manufacturing process</td>
</tr>
<tr>
<td>Zynteglo (bluebird bio)</td>
<td>Autologous CD34+ modified with lentiviral vector with proper β-globin gene</td>
<td>β-thalassemia</td>
<td>Global incidence – 1:100,000</td>
<td>1,525,000 € ($1,800 000)</td>
<td>Blood transfusion - side effects affect patients' life quality and expectancy; Allogeneic bone marrow transplantation available only for a minority of patients</td>
</tr>
<tr>
<td>(T-VEC) Talimogene laherparepvec (Imlygic)</td>
<td>Oncolytic herpes virus</td>
<td>Melanoma</td>
<td>55,000 € ($65,000)</td>
<td>To be applied after all other anti-cancer therapies failed</td>
<td></td>
</tr>
<tr>
<td>Exondys 51 (eteplirsen) (Sarepta)</td>
<td>Exon skipping oligonucleotide – Eteplirsen skips exon 51, golodirsen and vitolarersen exon 53</td>
<td>Duchenne muscular dystrophy</td>
<td>DMD incidence is about 1,500 boys; exon skipping is amenable to patients with given mutation (about 14% in case of eteplirsen; about 8% for golodirsen and vitolarersen)</td>
<td>255,000 € ($300,000/year)</td>
<td>Deflazacort (steroid) – $89,000/year (but prednisolone is much cheaper) – however, steroids do not cure DMD</td>
</tr>
<tr>
<td>Spintron (patisiran) (Alnylam)</td>
<td>siRNA targeting transthyretin mRNA</td>
<td>Hereditary transthyretin-mediated amyloidosis (hATTR)</td>
<td>About 50,000 patients worldwide</td>
<td>380,000 € ($450,000/year ~$10,000 per vial)</td>
<td>No effective treatment; potentially liver transplant in the early phase of the disease</td>
</tr>
</tbody>
</table>
ated with a risk of side effects, and hindered by lack of a sufficient number of donors. To overcome these limitations, the French team modified the patients’ bone marrow–derived HSPC with the gamma-retroviral vectors harboring the γc chain encoding sequence. Similar success was soon thereafter achieved by Adrian Trasher and co-workers working at the Great Ormond Street Hospital in London (Gaspar et al., 2004). The reinfused modified cells repopulated the bone marrow and the outcome of therapy was breathtaking, as the restoration of the immune system has been observed in 18 out of 20 treated patients (Kohn & Kohn, 2021). Unfortunately, at 2–14 years after the therapy, in 6 out of 20 treated patients, an uncontrolled proliferation of T-cells was observed which resembled the ALL (Staal et al., 2019; Kohn & Kohn, 2021). These patients have been effectively cured of leukemia but one, who unfortunately have died (Hacein-Bey-Abina et al., 2010). A detailed analysis revealed that the problem was caused by the vector-induced insertional mutagenesis. Although its integration is random, it appeared that incorporation into the promoter of the LMO2 gene, regulating proliferation of hematopoietic cells, caused the uncontrolled cell growth (Hacein-Bey-Abina et al., 2003). The studies have been stopped and the efforts have been concentrated on the development of safer vectors. It has been later demonstrated that the HIV-based lentiviral vectors can be manipulated in a way allowing their self-inactivation, limiting the risk of uncontrolled activation of the oncogenes (Staal et al., 2019; Kohn & Kohn, 2021). Accordingly, recent clinical trials performed in the USA demonstrated some effectiveness of the lentiviral vector-based gene therapy in X-SCID (De Ravin et al., 2016; Mamcarz et al., 2019), X-linked chronic granulomatous disease (Kohn et al., 2020), and recently they have been shown to be highly efficient in a clinical trial in 50 ADA-SCID patients (Kohn et al., 2021).

Interestingly, although exactly the same gammaretroviral vector was used, gene therapy of ADA-SCID immunodeficiency appeared to be very successful, with a 100% survival rate of patients over 2 to 13 years after therapy, and devoid of serious side effects (Cicalese et al., 2016). These results finally led to registration of Strimvelis (Hoggatt, 2016). Accordingly, Strimvelis is an approach in which the autologous CD34+ HSPC of patients suffering from ADA-SCID are transduced in vitro with a gammaretroviral vector harboring the proper ADA gene sequence. Strimvelis was the 2nd gene therapy officially registered in Europe, preceded by Glybera approved in 2012 (Ylä-Herttuala, 2012), which, however, has been withdrawn due to the very high price, lack of interest, and concerns of the cost-effectiveness benefits.

The several years-long clinical trials and observations performed at the San Raffaele Hospital in Milan have proven that Strimvelis is effective and safe for more than 40 children for whom the allogeneic haploidentical bone marrow transplantation was not possible or who did not qualify for the enzyme replacement therapy with ADA-PEG due to unwanted side effects (Ferrua & Aiuti, 2017). Currently, the longest survival reported after ADA-SCID gene therapy is 18 years, although five of the initial 22 subjects treated required additional allogeneic bone marrow transplantation or ADA-PEG therapy due to failure of gene therapy (Tucci et al., 2021). After registration Strimvelis has been applied in Milan in 12 subjects so far (Tucci et al., 2021). Similar positive results have been noted in patients treated in the frame of clinical trials in the UK and USA, with no evidence of serious insertional mutagenesis (Shaw et al., 2017).

What is crucial for the success of the ADA patients is also a prerequisite for expansion of the gene-corrected cells (for references see: High & Roncarolo, 2019). The myeloablative approach is, however, linked to the risk of toxicity, bone marrow failure, and secondary tumor development (Ferrari et al., 2021). Recently, the results of clinical trials on CD34+ cells modified with lentiviral vectors harboring the ADA gene have been published (Kohn et al., 2021). The studies performed in the USA and UK demonstrated a very high efficacy of the therapy, reaching almost 100% correction of CD34+ cells and restoration of the immune system. This approach may offer an additional level of efficacy and safety. Although Strimvelis is registered and its safety is demonstrated, one has to be aware of the still certain risks of side effects. Recently, the T-lymphoproliferative disease has been noted in a Strimvelis-treated patient three years after the therapy (Kohn et al., 2021), and studies are underway to elucidate if there is a link with gene therapy.

**Gene therapy of leukodystrophies**

Hematopoietic stem cells (HSCs) home to bone marrow niches where they can self-renew, differentiate and continuously generate blood cells and the immune cells. Gene therapy based on HSPC modification is applied in treatment of blood disorders, such as severe immunodeficiencies and anemias. It is also presumed that HSPC which differentiate into the macrophages, may contribute to the treatment of some neurological diseases, in which macrophages derived from modified hematopoietic progenitors could pass the blood-brain barrier and secrete the missing factors. Based on this rationale, bone marrow transplantation is considered to ameliorate the nervous system damage caused by the lack of proper metabolic enzymes. Allogeneic bone marrow transplantation has been thus applied for the treatment of leukodystrophies. However, this approach has limited efficacy and is prone to side effects. Therefore, as a potentially better alternative, genetic modification of autologous HSPC is tested for the treatment of adrenoleukodystrophy (ALD) or metachromatic leukodystrophy (Poletti & Biffi, 2019). In these trials, the lentiviral vectors have been used to modify patients’ CD34+ cells. Of note, the first phase clinical trials demonstrated effectiveness of the autologous gene therapy for X-linked ALD (Eichler et al., 2017) and early-onset metachromatic leukodystrophy (Biffi et al., 2013; Sessa et al., 2016). It appears, however, that the timing of the therapy is crucial and to achieve the effect it has to be initiated before the symptom develops. Nevertheless, there is a hope for further development and as an indication of that the European Medicines Agency (EMA) approved OTL-200 (Limbeldyntm) in 2020, which is comprised of autologous CD34+ cells transduced with lentiviral vector harboring human arylsulfatase-
A (ARSA) gene. This product, developed by Orchard Therapeutics in collaboration with the San Raffaele-Terleti Institute in Milan, is indicated for treatment of patients with metachromatic leukodystrophy. Its registration was based on at least seven year long clinical benefits observed in 30 out of 33 treated patients (Tucci et al., 2021; https://www.ema.europa.eu/en/news/new-gene-therapy-treat-rare-genetic-disorder-metachromatic-leukodystrophy).

Gene therapy of β-thalassemia and sickle cell disease

Zynteglo (betibeglogene autotemcel), produced by bluebird bio, is the recently registered gene therapy for treatment of β-thalassemia. In this approach, the retroviral vector harboring a proper human β-globin gene (βA-T87Q globin) is transduced to autologous CD34+ cells of the patients. The results of clinical trials have demonstrated a long, up to 56 months transfusion independence of the treated patients’ (Thompson et al., 2018), which made the Justification for the conditional approval of Zynteglo by EMA. The therapy was registered for patients who have to be 12 years of age or older, with transfusion-dependent β-thalassemia (High & Roncarolo, 2019).

The bluebird bio company is also elaborating on the development of a similar strategy for the sickle cell disease (SCD). Nevertheless, recently this study (ClinicalTrials.gov: NCT02140554) has been suspended when one of the participants developed an acute myeloid leukemia/myelodysplastic syndrome (Jones & DeBaun, 2021).

The very interesting strategy for therapy of β-thalassemia and SCD is currently tested with the application of gene editing approaches. Besides expression of a proper β-globin gene, which is mutated in these diseases, researchers are trying to elaborate one restoration of the fetal hemoglobin expression. As the gene for the fetal γ-chain is not mutated in the patients, and it has been active when in utero, its therapeutic expression can be potentially safer, as there will be no immune response to the fetal globin. Recently, the results of clinical trials of a few patients have been published, and are discussed below (see: Gene editing).

FIRST REGISTERED GENE THERAPIES

Although Strimvelis is the first effectively applied registered gene therapy, it was not the first one that was officially approved. In 2003, the Chinese medical agency approved Gendicine, an adenoviral vector harboring correct p53 for use together with radiotherapy in patients with the head and neck cancer (Guo & Song, 2018). However, the effectiveness of Gendicine is disputable and it has to be noted that exactly the same strategy (Senzer & Nemunaitis, 2009), despite years of clinical trials, did not receive authorization from FDA in the USA.

In 2012, EMA has registered Glybera, an AAV1 vector harboring the lipoprotein lipase (LPL) gene, for application in familial LPL-deficient patients (Ylä-Herttuala, 2012), a very rare disease characterized by acute pancreatitis. Its registration was associated with discussion on the real effectiveness of Glybera. These concerns and the high cost, exceeding one million Euro, influenced application of the therapy, which after registration was in fact given to only one patient and finally this medicine was withdrawn from the market.

AAV-BASED GENE THERAPIES

AAV vectors are small DNA vectors, built by single-stranded DNA containing 4.8 kilobases nucleotides (for review and references see: Li & Samulski, 2020). The original AAV virus contains only two genes, rep encoding proteins responsible for viral replication, and cap encoding the capsid proteins and an assembly-activating protein. The AAV vectors have been considered as particularly promising tools for gene therapy due to wild type AAV’s capacity to integrate into a specific site on the 19th chromosome (19q13.4 qtr; AAVS1). Moreover, due to the fact that AAV were not linked to any known disease and hence were recognized as nonharmful, and because of their specific integration site, they were considered as particularly promising for therapy of inherited diseases. However, during preparation of the vectors, when the rep and cap genes are removed, the specific integration capacity is lost. Then it appeared that integration is dependent not only on the presence of the ITR sequences at the 5’ and 3’ end of AAV, but also requires the rep protein. However, due to the small capacity of AAV’s, removal of the rep gene is necessary, moreover, the rep proteins are involved in viral replication, induce immune response and when expressed at the high level are toxic for the cells. Nevertheless, the ease of manipulation of the AAV vectors, several existing serotypes, and the overall safety, resulted in their widespread application despite the loss of specific integration. Moreover, when AAV vectors target the non-dividing cells, such as neurons or muscles, they can persist for a long time even without integration (although some integration, but not a specific ones, can be still achieved due to the ITR sequences).

The safety of AAVs was supported by the lack of known diseases caused by these viruses. Nevertheless, in the course of gene therapies performed, it was revealed that preexisting immunity (AAV neutralizing antibodies), as well as induction of the immune response when high doses of AAV vectors are delivered, can result in an aggravated inflammatory response. This problem has been observed in some gene therapy trials of hemophilia, in which it was diminished with corticosteroids. Unfortunately, recently in trials of myotubular myopathy two unexpected deaths had occurred. However, this might be linked to a higher dose applied in these patients, as the patients receiving a lower amount of AAV did well and demonstrated improvement (Sun & Roy, 2021).

Nevertheless, the AAV vectors are among the most successful in regard to clinical gene therapies. So far, three AAV-based gene medicines have been registered, although as mentioned, AAV1 Glybera has been withdrawn. However, AAV9 Zolgensma (for treatment of spinal muscular atrophy) and AAV2 Luxturna (for treatment of the Leber’s congenital amaurosis) appear to be effective. Overall, the AAV vectors are used so far in more than 200 human studies (Sun & Roy, 2021).

Luxturna

Inherited retinal diseases cause visual disability with a high frequency of 1:1000. Nevertheless, these diseases are heterogeneous and comprise a large group of more than 300 monogenic diseases (for references see: Cideciyan et al., 2021). Hence, various genetic strategies might be necessary to treat them.

Mutation in the RPE65 gene leads to the damage of retinal pigment cells and finally results in the blindness of the affected patients, creating one of the groups of
Leber congenital amaurosis, the most severe and childhood-onset blindness (Chen et al., 2021), RPE65 encodes an enzyme converting all-trans-retinyl ester to 11-cis retinol, a necessary component of the visual cycle in the retinal pigment epithelium. An AAV vector harboring the RPE65 gene gained approval by FDA after a phase III clinical trial and a 4-year follow-up which demonstrated effectiveness of the therapy. It is sold under the name Luxturna (voretigene neparvovec-ryzl) by Spark Therapeutics in the USA and by Novartis in other countries (Maguire et al., 2021) (Table 1 and 4).

The efficacy of AAV in the treatment of blindness is the consequence of several factors. First, the eye is immune-privileged, hence the immune response against the transgene and the vector is limited. Second, although treatment of blindness requires permanent expression of a therapeutic gene and despite the fact that the AAV vectors do not specifically integrate, this does not hinder transfection efficacy as the transduced epithelial pigment cells do not divide.

Localized expression of RPE65 can treat this form of inherited blindness, however, one has to remember that not all of these diseases qualify for AAV delivery due to the size of the affected gene. Accordingly, in another form of Leber’s congenital amaurosis, caused by a mutation in the CEP290 gene, gene-editing strategy started to be tested recently (Ledford, 2020) (see below).

One also has to note the stem cell-based therapy approaches to treat a genetic blindness caused by improper retina functioning. The pigment epithelial cells obtained by differentiation of embryonic stem cells (ESC) are tested in the Stargardt’s disease and the results of the early trials are promising (Schwartz et al., 2015). The ESC-derived pigment epithelial cells are also applied for the treatment of adult macular degeneration (da Cruz et al., 2018). In Japan, early-stage clinical trials with induced pluripotent stem cells (iPSC)-derived epithelium have been initiated in such patients. In this approach, performed so far in one patient, the pigment epithelial cells are obtained by differentiation of autologous iPSC (Mandai et al., 2017).

Although stem cell therapies are not “classical” gene therapy, one has to remember that the action of cells obtained by differentiation of stem cells is to restore proper expression of the missing gene(s). In such a case, stem cells, such as HSPC, can be considered as the vehicle of the proper gene. These can also be differentiated cells when direct delivery of stem cells is not possible due to the risk associated with pluripotent stem cells (ESC or iPSC), which when undifferentiated, can form teratomas in the patients.

GENETIC THERAPIES FOR SPINAL MUSCULAR ATROPHY

After cystic fibrosis, spinal muscular atrophy (SMA) is the 2nd most common autosomal recessive disorder in humans, and it is also the most common genetic cause of death in childhood (Wirth, 2021; Wirth et al., 2020), with the incidence from 1:6000 to 1:10 000. SMA is caused by a mutation in the SMN1 (survival motor neuron) gene. SMN1 is a ubiquituous protein, involved in transcriptional regulation and intracellular trafficking, and its lack particularly results in a selective motor neuron death. Accordingly, the most common feature of SMA is the loss of spinal motor neurons, and due to the impairment in the functions of neuromuscular junctions (NMJ), the disease is characterized by a progressive weakness and atrophy of the proximal voluntary muscles (Wirth, 2021; Wirth et al., 2020).

As described in a very comprehensive recent review (Wirth, 2021), the vast majority of SMA patients (96%) carry a homozygous deletion of exon 7 and 8 or exon 7 alone, while others have point mutations. Based on the severity of the disease, it is classified into six types. The SMA0 type is considered to comprise less than 1% of SMA patients, and newborns survive only a few days to weeks. The SMA1 type is the most common one, involving 50% of the SMA cases and 1:10,000 live births. The children affected never sit up and usually die before the age of 2 years. The SMA2 patients (30%) can sit up, but never walk and their survival is reduced similarly to SMA3a patients (10%), who start to walk but finally lose ambulation at 18 months to 30 years. In two other subtypes, SMA3b (9%) and SMA4 (less than 1%) there are some walking impairments but occur later in life and the life span of the patients is not affected (Wirth, 2021).

Mutation in the SMN gene in mice is embryonically lethal. In humans, the severity of SMA depends on the number of copies of SMN2, the second, almost identical gene, whose duplication is specific only for primates (Wirth et al., 2020). SMN2 differs from SMN1 only in five nucleotides. However, a point mutation in exon 7 results in its exclusion during alternative splicing, and the amount of the normal SMN protein is thus reduced. Because of that, the severity of SMA depends on the number of SMN2 copies in the SMA patients. The majority of SMA1 type patients have only two copies of the SMN2 gene (73%), while about 7% have only one copy, and 20% have three copies. In contrast, 78% of SMA2 patients have three copies of the SMN2 gene, hence despite the mutation the amount of normal SMA protein generated is sufficient to allow the survival of patients to adulthood. Still, about 16% of SMA2 patients have only two SMN2 copies and therefore demonstrate more severe conditions. On the other hand, majority of the SMA3a and SMA3b patients have either three or four copies of SMN2, and the persistent walking ability in SMA3b is thanks to a larger amount of SMA protein derived from four copies of the SMN2 gene present in 60% of these patients (Wirth, 2021).

The first effective genetic therapy for SMA was nusinersen, registered by FDA in 2016. Nusinersen (with brand name Spinraza), is an intrathecally delivered sense oligonucleotide (for review see: Wirth et al., 2020). The injection route is due to the incapacity of the oligonucleotide to pass the blood-brain barrier which requires its direct delivery to the cerebrospinal fluid. Nusinersen is targeted to the splicing site of exon 7. Its binding to pre-mRNA allows inclusion of exon 7 in the generated mRNA, by blocking recruitment of the splicing repressor hnRNP-A1 (Wirth, 2021). As a consequence, the amount of a proper SMA protein is significantly increased. Due to the limited half-life of the oligonucleotides, the therapy has to be repeated and the four injections per year are very costly, reaching $ 375,000 per year (Table 4). Nevertheless, clinical trials have demonstrated the Nusinersen’s effectiveness in patients of all SMA types and the therapy is registered both in the USA and Europe. Moreover, in many countries, including Poland, the treatment is covered by the state health insurance. According to a recent review, so far over 10,000 patients are treated worldwide (Wirth, 2021). When Nusinersen was applied to presymptomatic individuals who probably will develop SMA1 or SMA2, the study showed that treatment resulted in independent walking of almost
90% of patients (De Vivo et al., 2019; for review see: Mendell et al., 2021b). In 2020, Risdiplam (Evrysdi; RG7916), an oral small molecule targeted therapy for SMA has been registered (Baranello et al., 2021). The final outcome achieved by Risdiplam is similar to Spinraza, because Risdiplam also increases the level of properly spliced mRNA of SMN2. Nevertheless, this is not genetic therapy but direct targeting of a mutation with small molecule. Risdiplam works by facilitating recruitment of the U1-snRNP particles to the splice donor site of intron 7 of the SMN2 gene (Wirth, 2021). This compound has to be taken daily and may offer an advantage over Spinraza due to the mode of delivery and the (future) cost. However, the price still remains high, being $100,000–340,000/year, depending on the weight of the patient (Wirth, 2021).

In 2019, the FDA approved a classical gene therapy for SMA. Zolgensma (AVXS-101; onasemnogene aberparvovec), is an AAV9 type vector with the SMN1 gene driven by a strong chicken β-actin promoter (Mendell et al., 2017). It is delivered only once by a systemic intravenous injection, which makes this approach particularly attractive. The outcomes of Zolgensma application in children with SMA were spectacular in the phase I trial. In some cases, the children with SMA1 type not only survived beyond the previously not passed barrier of two years, but even gain the ability to walk (Wirth, 2021). Ongoing analysis confirms the effectiveness of this therapy (Mendell et al., 2021a). In Europe, Zolgensma is applied to patients with three or less copies of SMN2, but its application is limited to children of less than two years old and below 13.5 kg of weight in the USA and up to 21 kg in EU, due to the increased with age risk of gaining the AAV antibodies during typical infections occurring in children (Wirth, 2021). Zolgensma’s serious limitation is the enormously high price of $2.1 million which makes it the most expensive medicine.

The history of the development of the treatment of SMA demonstrates the power of genetic approaches. Several features of the SMN1 gene and the nature of the disease facilitated the establishment of this effective AAV therapy. The small size of the SMN1 gene allows its cloning into the AAV vector. Comparison with Duchenne muscular dystrophy (DMD), another common genetic disease, caused by mutations in the dystrophin gene on the X-chromosome (for review see: Loboda & Dulak, 2020) also shows how a variety in the disease mechanisms and the extent of the tissues to be affected hinders the development of effective therapies for DMD despite enormous knowledge generated. As described, for SMA there are now three registered medications targeting the genetic cause of the disease. For DMD there are four registered antisense oligonucleotides – eteplisn, casimersen and vitalorsen (Table 1), causing exon skipping and restoring the reading frame which allows partial restoration of a truncated dystrophin expression. However, their effectiveness is limited and the approval of them by the FDA was conditional (Loboda & Dulak, 2020; Ferlini et al., 2021; Winkle et al., 2021). Moreover, as SMN is expressed from the SMN2 gene, correction of SMN2 splicing or gene transfer of SMN1 and consequently increased production of SMN protein does not induce an immune response, unlike in the case of DMD (for reviews see: Loboda & Dulak, 2020; Wirth, 2021).

Nevertheless, despite efficient means to increase the SMN protein level in SMA patients, the problems with the lack of SMN during fetal development and not sufficient level of this protein in other organs will undoubtedly have to be addressed when the treated patients will grow. The comorbidities in other organs, even with improvement in the central nervous system (targeted by the intravenously delivered antisense oligonucleotides) have to be carefully monitored (Wirth, 2021). A very early initiation of treatment might be one of the key features here (Ramos et al., 2019; Kong et al., 2021), as observed in a mouse model of SMA, in which elevation of the SMN levels during the first three days after birth prevented the disease, while treatment after day 5 was almost ineffective (Kariya et al., 2014). However, achieving a high level of the SMN protein for a long time might also cause problems, as toxic effects of high AAV9-SMN overexpression have been observed in aged mice (citation of conference presentation in Wirth, 2021). Elaborating on other therapies, relying on the disease-modifying pathways has to be also considered.

ANTI-CANCER GENETIC THERAPIES

At the beginning of gene therapy, adenoviral vectors have been considered as the very promising tools for treatment of diseases in which permanent expression is not required. This particularly concerns cancers, but these vectors have been also tested for other conditions, including the monogenic inherited diseases. A large capacity of the genome, which in the case of the so-called gutless vectors can harbor even up to 36 kb of nucleotides (Table 2) was regarded as the real advantage (Jóźkowicz & Dulak, 2005). In addition, the relative ease in the production of large titers of adeno vectors makes them an excellent tool for the large-scale synthesis necessary for clinical trials. The concerns were related to the high inflammatory features of adenoviruses, which were dependent both on the preexisting immunity, as well as the necessity of using high viral titers which due to the expression of viral proteins exposed the patients to the risk of a systemic inflammatory reaction (for reviews see: Bessis et al., 2004; Liu & Muruve, 2003).

Clinical gene therapy trials of cancer constitute the largest number of so far performed or ongoing gene therapies. Nevertheless, despite huge efforts, successful outcomes did not appear for a long time. Apparently, the complexity of cancer diseases and mechanisms hinders applications of these and similar approaches.

Besides the already mentioned p53-gene therapy of the head and neck cancer, among numerous studies which have not led so far to a formal approval is the suicide gene therapy for glioblastoma multiforme (GM), the most malignant brain tumor. The principle of suicide therapy relies on a localized delivery of the gene encoding the protein – an enzyme, which is able to metabolize the then intravenously delivered prodrug, converting it into an effective drug killing the cells in which the suicide gene is expressed (for review: Sheikh et al., 2021)). In regard to GM, a very promising approach was a clinical trial coordinated by Seppo Yla-Herttuala from the University of Eastern Finland in Kuopio. After tumor resection, the adeno viral vector harboring a herpes virus thymidine kinase (HSV-TK) (Cerepro, sintamogene ceradenovec) was applied into the tumor area of the brain and the patients were injected with ganciclovir, the substrate for TK, which upon phosphorylation blocks DNA replication. The patients were concomitantly treated with temozolomide, the chemotherapy of choice in GM. Despite very promising initial clinical trials (Immonen et al., 2004), randomized phase 3 trials performed in several European countries did not show the real advantage of the HSV-TK gene therapy applied.
together with temozolomide over patients treated only with chemotherapy (Westphal et al., 2013), and this approach was not approved by EMA (Cerepro: Withdrawn application|European Medicines Agency [europa.eu]).

The success of gene therapies in cancer is on the other hand exemplified in ex vivo approaches, aimed at boosting the patients’ cell capacity to kill tumor cells. Genetic modification of the patients’ T lymphocytes with lentiviral vectors containing a gene encoding chimeric antigen receptors (CAR) arms these cells against the tumors (Milone & O’Doherty, 2018). The chimeric receptors in the CAR-T therapies registered so far mostly target the CD19 protein common on the surface of B cells. This is the mechanism of action of Tisagenlecleucel (Kymriah) and axicabtagene ciloleucel (Yescarta) for treatment of B-cell acute lymphoblastic leukemia and diffuse large B-cell lymphoma (a type of non-Hodgkin lymphoma), respectively. In 2020 and 2021, Tecartus (brexucabtagene autoleucel) for mantle cell lymphoma, Abecma (idecabtagene vicleucel) for multiple myeloma and Breyanzi (lisocabtagene maraleucel) for large B-cell lymphoma were approved (Ellis et al., 2021; Munshi et al., 2021) (Table 1, Table 2). Abecma targets a B-cell maturation antigen (BCMA), unlike the other CAR-T cell therapies registered so far, which target the CD19 protein.

Gene therapy of cancer can be also executed by viruses able to fully replicate only in the tumor cells. These oncolytic viruses, due to some mutations, cannot perform the full cycle in normal cells, but they can effectively replicate and finally kill the tumor cells lacking e.g. the correct p53 gene (Kaufman et al., 2016). Although such an approach is not classical gene therapy, the fact that the vectors can be additionally manipulated makes them an example of genetic therapy. In Europe and the USA, in 2015, the IMLYGIC (T-VEC, talimogene laherparepvec) has been registered. This is a herpes simplex virus additionally harboring the CSF3 gene (coding for granulocyte-macrophage colony-stimulating factor; GM-CSF) which is applied for unresectable melanoma recurrent after initial injection (for review see: Koch et al., 2020). However, the real efficacy of this therapy still needs verification (Larocca et al., 2020).

RNA AS THERAPEUTICS

The field of RNA was raised to a great importance in the 21st century. Discovery of efficient mechanisms of gene silencing by siRNA, followed by elucidation of the important roles of microRNAs, created hopes for applications of these strategies for therapeutic purposes. However, despite long efforts, clinical applications were limited until recent years, when the siRNA targeting the transthyretin amyloid mRNA in hereditary variant transthyretin amyloidosis patients (hATTRv) was registered in 2018 by the FDA and EMA. Patisaran (Urits et al., 2020) can be used in patients suffering from this very rare disease affecting about 5,000–10,000 people worldwide. Of note, for the hATTR treatment an antisense oligonucleotide inotersen has been also recently registered (Benson et al., 2018) (Table 1). Currently, a few other siRNA therapeutics have been approved by the EMA and/or FDA. Among them are givosiran for acute hepatic porphyria, inclisiran for hereditary familial hypercholesterolemia, and lumasiran for primary hyperoxaluria type 1 (Table 1) (for review see: Winkle et al., 2021)). And, as is very well known, the COVID-19 pandemic demonstrates the utility of mRNA anti-SARS-CoV-2 vaccines, as well as, of course, those based on adenoviral vectors (for review see: Sadarangani et al., 2021).

PROMISING EXAMPLES OF EXPERIMENTAL CLINICAL TRIALS OF GENE THERAPY

Hemophilia

Hemophilia is the most common X-linked disease. In hemophilia A, the inability of blood clotting is due to the lack of a proper gene for factor VIII, while in hemophilia B for factor IX. The factor IX, due to the size of its cDNA, is a good candidate for AAV-based gene therapies. Clinical studies, preceded by long-term experiments in dogs (Manno et al., 2006), have demonstrated the effectiveness of intravenous administration of AAV with factor IX cDNA to target the liver of hemophilia B patients (Manno et al., 2006; Nathwani et al., 2011; Nathwani et al., 2014; George et al., 2017). However, problems appear with the pre-existing antibodies to AAV capsids. Similar drawbacks can be encountered in the treatment of hemophilia A, where additionally due to the very large size of factor VIII cDNA, only its truncated form can be applied by AAVs (Rangarajan et al., 2017).

Epidermolysis bullosa (EB)

EB comprises several severe rare diseases in which the lack of various proteins, such as collagen XVII or laminins, causes continuous detachment of the epidermis associated with severe, often extreme suffering of the patients. There are no effective treatments and together with continuous pain, as well as a permanent risks of infections, some patients are under the threat of development of cancer (for review see: De Luca et al., 2019).

This is the case in junctional EB in which a mutation in the LAMB3 gene results in the lack of laminin 332. In the previous decade, the Italian scientists, led by Michele De Luca and Graziella Pellegrini, performed an initial trial in an adult EB patient, whose epidermal stem cells were isolated from the undamaged part of the skin and modified ex vivo with retroviral vector harboring the LAMB3 gene (Mavilio et al., 2006). The modified, cured epidermis was cultured and small pieces were placed on the damaged skin area of the patient where they adhered and partially restored the healthy skin and persisted for more than six years (De Rosa et al., 2014).

In 2015, the same group of Italian researchers working together with German clinicians saved the life and restored the healthy skin in a 7-year old boy suffering from this disease. The conditions of this patient before the treatment were very poor and he was kept in a pharmacological coma due to the damage of almost 70% of his skin and recurrent sepsis caused by infections with Staphylococcus aureus and Pseudomonas aeruginosa. Large fragments of healthy epidermis obtained from the patient’s epidermal stem cells modified with a retroviral vector harboring proper LAMB3 gene were generated in the laboratory and placed on the extremely affected body of the boy. The spectacular results demonstrate almost total healing of the skin and two years after the treatment the boy was able to attend school and participate in sport exercises, an activity not available for children with this severe disease (Hirsch et al., 2017). Five years after treatment, the boy’s conditions are very good (Prof. Graziella Pellegrini, personal communication).
Lysosomal storage diseases

Another recent example can be the lentivirus-mediated gene therapy for the ultra-rare Fabry disease, a lysosomal disorder in which patients lacking the α-galactosidase A (α–Gal A) enzyme develop a progressive lysosomal accumulation of globotriaosylceramide, which besides numerous painful syndromes finally leads to a stroke and myocardial infarction. In a recent gene therapy clinical trial, five patients have been treated with autologous CD34+ cells transduced with lentiviral vector harboring the α–Gal A sequence. Interestingly, within a week all patients started to produce a near-normal level of the enzyme and the effects have already persisted in at least one patient for three years post-infusion. Three patients decided to discontinue the enzyme replacement therapy (Khan et al., 2021).

Several other lysosomal storage diseases (LSD) are also the target of pre-clinical and in some cases early clinical trials of gene therapy. As in the case of the mentioned above metachromatic leukodystrophy (Tucci et al., 2021) and Fabry disease (Khan et al., 2021), clinical studies so far concentrate on the ex vivo gene therapy of autologous hematopoietic progenitor cells transduced with lentiviral vectors harboring a relevant therapeutic gene. Recent comprehensive reviews (Tucci et al., 2021; Massaro et al., 2021) describe in more details the trials in which the CD34+ cells are to be transduced with N-sulfoglucoamin sulfohydrolase cDNA for treatment of mucopolysaccharidosis type III, α-l-iduronidase for the Hurler variant of mucopolysaccharidosis type I, β-glucocerebrosidase cDNA for the Gaucher disease and the cystinosin gene for cystinosis. Some of the LSDs are also considered as targets for gene editing strategies (Massaro et al., 2021) and a first one was initiated in a patient with type II mucopolysaccharidosis (the Hunter’s syndrome) (see: First in vivo human genome editing trial, Nature Biotechnology, January 2018).

GENE EDITING

Currently, gene editing approaches particularly concentrate on the application of CRISPR/Cas9, due to the simplicity of designing the tools to specifically target a gene to mutate or repair it. In contrast to the zinc-finger or TALEN strategies, which historically preceded CRISPR/Cas9 (Wood et al., 2011), the latter does not require the design of the protein to target the gene of interest. The ease to program and synthesize the single guide RNAs (sgRNAs) and relative simplicity to deliver them together with the Cas9 enzyme (they can be both transduced with the AAV vectors, which makes them suitable for in vivo approaches) led relatively quickly to initiation of clinical trials which will be discussed later. Nevertheless, historically, the first clinical gene editing approach was performed with application of the zinc-finger nuclease strategy (ZFN) (Tebas et al., 2014).

ZFN consists of a tandem array of Cys2His2 zinc fingers, combined with the FokI nuclease. Each tandem array recognizes approximately three base pairs of DNA. Importantly, the FokI nuclease, which is bacterial type II restriction endonuclease, does not recognize any specific DNA sequence but it gains the cutting specificity when it dimerizes. Accordingly, the properly designed zinc finger proteins (ZFP) target the specific regions on the opposite DNA strands and allow dimerization of FokI connected with ZFP. Cutting of DNA initiates the repairing mechanisms and the DNA can be corrected either by homologous recombination (HR), when the correct sequence homologous to the targeted region is delivered to the cells, or by non-homologous end joining (NHEJ). HR is mostly applied when the aim is to repair the mutation, and NHEJ is applied when a mutation in the sequence is desired (for review see: Urnov et al., 2010). Observation of the so-called “Berlin patient”, in whom the bone marrow transplantation for treatment of leukemia also caused a remission of an HIV infection, created the background for gene editing intervention in AIDS patients. In this patient, the transplanted bone marrow was derived from the donor who had a mutation in the CCR5 gene. The deletion of 32 bp in CCR5 sequence did not impair the donor’s CD4+ T-cell function, but it rendered these cells resistant to infection to HIV and led to the diminishment and disappearance of the HIV viral load (Zou et al., 2013).

This observation was the rationale for a clinical trial in 12 AIDS patients, whose T cells have been ex vivo treated with adeno-viral vector-based zinc-fingers to mutate the CCR5 (Tebas et al., 2014). The infusion of such edited cells resulted in a quick increase in the number of CD4 T cells which persisted in the circulation for almost one year and the blood level of HIV DNA decreased in most of the patients (Tebas et al., 2014). Recently, the same group has performed a similar trial in which the CCR5 in T lymphocytes has been targeted by CRISPR/Cas9 (Tebas et al., 2021). However, mixed results of the studies indicate that although it has a strong biological rationale, its effectiveness needs improvement. Of note, the FokI enzyme used in ZFN and TALENs was introduced by Wacław Szybalski, Anna Podhajska and S.C. Kim as the universal restriction enzyme (Podhajska & Szybalski, 1985; Kim et al., 1988), and then proved useful in the Human Genome Project.

The simplicity of the CRISPR/Cas9 editing makes it rather an obvious choice for future clinical developments. In 2020, a first clinical trial has been initiated in patients suffering from Leber’s congenital amaurosis type 10 (LCA10), the most common form of LCA (about 30%), caused by a mutation in the CEP290 gene (Ledford, 2020). This is a different form than RPE65-LCA, which can be now treated with Luxturna, as discussed above. The CEP290 gene is much bigger than RPE65 (the cDNA for CEP290 is 8000 nucleotides) (Burnight et al., 2014), and hence the AAV vectors cannot be used to deliver it to the retina (Ledford, 2020). It is hoped that with the CRISPR/Cas9 approach, correction of the mutation should restore the proper level of CEP290 in photoreceptors.

Recently, the first results of the clinical application of CRISPR/Cas9 strategy for the treatment of one patient with transfusion-dependent β-thalassemia and one with SCD have been published. Although the mutations in both diseases are different, both concern the β-globin gene. The same gene editing strategy could be applied in both diseases, as the target for CRISPR/Cas9 can be the BCL11A gene – an erythroid-specific enhancer repressing γ-globin expression, hence switching off this fetal hemoglobin production after birth. In these two patients, their CD34+ cells have been ex vivo targeted with CRISPR/Cas9 directed to BCL11A to mutate it and in this way to abolish its expression. The patients received an infusion of their own edited cells after myeloablation and one year later, both patients demonstrated a high level of BCL11A edition in the bone marrow and blood. Importantly, an increase in fetal hemoglobin, transfusion independence, and elimination of vaso-occlusive
episodes, the latter in the patient with SCD, have been observed (Frangoul et al., 2021).

Moreover, gene editing can allow correction of mutation in the β-globin gene of sickle cell disease patients, although the low efficacy of homology-directed repair in HSPC must be overcome. A new approach of “base editing” offers an additional promise, in which even the silencing of BCL11A can be combined with the repair of the globin mutation (Zeng et al., 2020).

In another study published at the same time, Esrick et al. have used the shRNA delivered by lentiviral vectors to CD34+ cells to silence BCL11A. Six SCD patients have been treated and followed up for at least six months, during which a robust induction of fetal hemoglobin was observed and clinical manifestations of SCD were reduced or absent (Esrick et al., 2021).

SUMMARY

Since Elisabeth and Waclaw Szybalski performed the first permanent modification of mamalian cells thanks not only to the brave and generous idea, but also a bit of luck always necessary in breakthrough experiments, numerous approaches have been established, making genetic modifications not only the obvious and indispensable research tools, but also consequently proving its medical rationale and utility. Correction of the HPRT-deficient cells with DNA isolated from normal cells was possible thanks to the high content of calcium ions, which neutralized the negative charge of DNA and allowed its entrance into the HPRT-negative cells. In the late 60ties and 70ties of the 20th century, calcium chloride became the routine tool for nonviral gene delivery. The development of numerous other neutralizing vehicles, like cationic liposomes, polyamines and dendrimers allows the effective transfection of cells in vitro. Recently, application of liposomes for delivery of RNA antisense-COV-2 vaccines has demonstrated a large utility of this type of in vitro gene administration. The success of commercial gene therapy has been possible thanks to the enormous work of basic science researchers, elucidating the nature of viruses and modifying their properties for safe clinical applications. The potential for therapeutic genetic manipulation has been recently spectacularly increased thanks to the gene-editing technology. Due to their simplicity, the CRISPR/Cas9 based strategies are the first choice, but one has to remember that application of the universal FokI restriction enzyme, applied for the first time by Anna Podhajska and Wacław Szybalski to manipulate bacterial genome, has opened the possibility for use of the FokI protein in combination with zinc fingers or TALEN to modify the mammalian cells. The first choice, but one has to remember that application of the universal FokI restriction enzyme, applied for the first time by Anna Podhajska and Wacław Szybalski to manipulate bacterial genome, has opened the possibility for use of the FokI protein in combination with zinc fingers or TALEN to modify the mammalian cells. Establishment of this type of gene delivery: An overview of their evolution depending on routes of administration. Biotechnol. J. 10: 1370–1389. https://doi.org/10.1002/biot.201004881

REFERENCES


Cicalese MP, Ferrua F, Castagno L, Pajno R, Barzaghi F, Giannelli S, Dionisio F, Brigida I, Bonopane M, Casiraghi M, Toschuci A, Carlucci F, Grunebaum E, Adeli M, Bredius RG, Puck JM, Ste- paniak P, Tizzano J, Botelho RB, De Boever E, Reinhart R, Appleby J, Ciceri F, Roncarolo MG, Aiuti A (2016) Update on the help of Ms. Joanna Uchto-Bajołek is acknowledged. Currently, the author’s research on gene therapy technologies and stem cells is supported by grants MAESTRO 10 (2018/30/A/ NZ3/00412) from the National Science Center (NCN), CISTEM MSCA RISE (Z/H20/00023 from H2020 program (grant agreement No. 778354) and NMJ-on-a-chip (UMO-2019/01/Y/NZ3/00012) from JPN initiative (Horizon 2022) and NCN. The author reports no conflict of interest.

Cicedyan AV, Jacobson SG, Ho AC, Garafalo AV, Roman AJ, Su-
p://doi.org/10.1038/nm.3179


Kahn A, Barber DL, Huang J, Rupar CA, Rip JW, Auwera Blais C, Bou-


Cicedyan AV, Jacobson SG, Ho AC, Garafalo AV, Roman AJ, Su-
p://doi.org/10.1038/nm.3179


Kahn A, Barber DL, Huang J, Rupar CA, Rip JW, Auwera Blais C, Bou-


